ERBB2 and breast carcinoma: Whether in HR+ or HR− subtype, HER2-positive breast cancer was characterized by gains in 17q12 (ERBB2, CDK12, HNF1B, RAD51D), and almost no gains of 17q12 were present in the other subtypes.